Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0194-0499 plus semaglutide for NASH-related fibrosis
2020-003566-39Phase 2Active
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing NNC0194-0499 + semaglutide with Placebo (2 arms). Primary endpoint: Improvement in liver fibrosis without worsening of NASH. Started Jun 2021; status: active.
02
Drugs
nn9500semaglutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2020-003566-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003566-39.